Vnitr Lek 2015, 61(9):760-761

Tyrozinkinázové inhibitory v léčbě starších pacientů s chronickou myeloidní leukemií - editorial

Daniela Žáčková
Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.

Received: July 29, 2015; Published: September 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žáčková D. Tyrozinkinázové inhibitory v léčbě starších pacientů s chronickou myeloidní leukemií - editorial. Vnitr Lek. 2015;61(9):760-761.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408-2417. Go to original source... Go to PubMed...
    2. Deininger M, O'Brien SG, Guilhot F et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: Abs. No. 1126. Dostupné z WWW: <https://ash.confex.com/ash/2009/webprogram/Paper23968.html>. Go to original source...
    3. Hoffmann VS, Baccarani M, Hasford J et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904CML patients in 20 European Countries. Leukemia 2015; 29(6): 1336-1343. Go to original source... Go to PubMed...
    4. Rohrbacher M, Berger U, Hochhaus A et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23(3): 602-604. Go to original source... Go to PubMed...
    5. Bělohlávková P, Voglová J, Radocha J et al. Má věk nemocných s chronickou myeloidní leukemií při léčbě imatinibem vliv na dosaženou léčebnou odpověď? Vnitř Lék 2015; 61(9): 785-791. Go to PubMed...
    6. Kantarjian HM, Keating MJ, McCredie KB et al. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J 1987; 80(10): 1228-1232. Go to original source... Go to PubMed...
    7. Björkholm M, Ohm L, Eloranta S et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29(18): 2514-2520. Go to original source... Go to PubMed...
    8. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 2008; 93(10): 1544-1549. Go to original source... Go to PubMed...
    9. Cortes J, Talpaz M, O'Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98(6): 1105-1113. Go to original source... Go to PubMed...
    10. Rosti G, Iacobucci I, Bassi S et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007; 92(1): 101-105. Go to original source... Go to PubMed...
    11. Latagliata R, Breccia M, Carmosino I et al. "Real-life" results of front-line treatment with Imatinib in older patients (ge; 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010; 34(11): 1472-1475. Go to original source... Go to PubMed...
    12. Gugliotta G, Castagnetti F, Palandri F et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117(21): 5591-5599. Go to original source... Go to PubMed...
    13. Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118(3): 686-692. Go to original source... Go to PubMed...
    14. Le Coutre PD, Turkina A, Kim DW et al. Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase: a subanalysis of the ENACT (Expanding nilotinib access in clinical trials) study. Blood 2009; 114: 3286. Dostupné z WWW: <https://ash.confex.com/ash/2009/webprogram/Paper19517.html>. Go to original source...
    15. Latagliata R, Breccia M, Castagnetti F et al. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res 2011; 35(9): 1164-1169. Go to original source... Go to PubMed...
    16. Breccia M, Luciano L, Latagliata R et al. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res 2014; 38(10): 1173-1176. Go to original source... Go to PubMed...
    17. Iurlo A, Ubertis A, Artuso S et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med 2014; 25(1): 63-66. Go to original source... Go to PubMed...
    18. Breccia M, Latagliata R, Stagno F et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011; 96(10): 1457-1461. Go to original source... Go to PubMed...
    19. Latagliata R, Ferrero D, Iurlo A et al. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging 2013; 30(8): 629-637. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.